share_log

T2 Biosystems | CORRESP: CORRESP

T2 Biosystems | CORRESP: CORRESP

T2 Biosystems | CORRESP:信函
美股SEC公告 ·  06/01 01:41

Moomoo AI 已提取核心信息

T2 Biosystems, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on May 28, 2024. The company seeks to have the registration statement become effective by 4:30 p.m. Washington D.C. time on June 4, 2024, or as soon as possible thereafter. This request was made under Rule 461(a) of the Securities Act of 1933, as amended. T2 Biosystems has asked to be notified of the registration's effectiveness via a phone call to N. Danny Shulman of Latham & Watkins LLP and also expects a written confirmation. John Sperzel, President, CEO, and Chairman of the Board of T2 Biosystems, signed the request.
T2 Biosystems, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on May 28, 2024. The company seeks to have the registration statement become effective by 4:30 p.m. Washington D.C. time on June 4, 2024, or as soon as possible thereafter. This request was made under Rule 461(a) of the Securities Act of 1933, as amended. T2 Biosystems has asked to be notified of the registration's effectiveness via a phone call to N. Danny Shulman of Latham & Watkins LLP and also expects a written confirmation. John Sperzel, President, CEO, and Chairman of the Board of T2 Biosystems, signed the request.
t2 biosystems公司已正式要求证券交易所委员会(SEC)加速其于2024年5月28日首次提交的S-3表格注册声明生效日期。该公司希望在2024年6月4日美国华盛顿时间下午4:30或尽可能之后使注册声明生效。此请求根据1933年证券法第461(a)条修订案提出。t2 biosystems公司要求以电话形式通知Latham & Watkins LLP的N. Danny Shulman注册行动的生效,并期望得到书面确认。t2 biosystems的总裁,首席执行官和董事会主席John Sperzel签署了请求。
t2 biosystems公司已正式要求证券交易所委员会(SEC)加速其于2024年5月28日首次提交的S-3表格注册声明生效日期。该公司希望在2024年6月4日美国华盛顿时间下午4:30或尽可能之后使注册声明生效。此请求根据1933年证券法第461(a)条修订案提出。t2 biosystems公司要求以电话形式通知Latham & Watkins LLP的N. Danny Shulman注册行动的生效,并期望得到书面确认。t2 biosystems的总裁,首席执行官和董事会主席John Sperzel签署了请求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息